Suppliers and packagers for generic pharmaceutical drug: NINTEDANIB ESYLATE

NINTEDANIB ESYLATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Boehringer Ingelheim	OFEV	nintedanib esylate	CAPSULE;ORAL	205832	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0143-60	1 BOTTLE in 1 CARTON (0597-0143-60) / 60 CAPSULE in 1 BOTTLE	2014-10-15
Boehringer Ingelheim	OFEV	nintedanib esylate	CAPSULE;ORAL	205832	NDA	Boehringer Ingelheim Pharmaceuticals, Inc.	0597-0145-60	1 BOTTLE in 1 CARTON (0597-0145-60) / 60 CAPSULE in 1 BOTTLE	2014-10-15

NINTEDANIB ESYLATE MANUFACTURING SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

This report analyzes the global supply chain for nintedanib esylate, a tyrosine kinase inhibitor used in treating idiopathic pulmonary fibrosis and certain types of non-small cell lung cancer. Key manufacturing components, active pharmaceutical ingredient (API) suppliers, and critical raw materials are identified, alongside potential risks and strategic considerations for pharmaceutical companies.

WHO ARE THE PRIMARY MANUFACTURERS OF NINTEDANIB ESYLATE API?

The synthesis of nintedanib esylate is a complex multi-step process requiring specialized chemical expertise and manufacturing infrastructure. While the final drug product formulation is handled by originator companies and contract manufacturing organizations (CMOs), the production of the nintedanib esylate API itself is concentrated among a select group of chemical manufacturers. These manufacturers often operate under strict quality control regimes to meet regulatory requirements.

Manufacturer Name	Location(s)	Primary Focus	Notes
Boehringer Ingelheim	Germany, USA	Originator API production; proprietary	Holds primary patents and manufacturing know-how.
Hangzhou Zhongxin Chem	China	Generic API production; custom synthesis	A significant player in the generic API market.
Jiangsu Hansoh Pharmaceutical	China	Generic API production; contract manufacturing	Known for its broad API portfolio.
Laurus Labs	India	Generic API production	Emerging player with increasing API capacity.
Neuland Laboratories	India	Generic API production; contract manufacturing	Established Indian API manufacturer.

Boehringer Ingelheim, as the originator company, likely maintains proprietary control over specific manufacturing processes and intermediates, potentially limiting direct competition for the early stages of API synthesis. However, as patents approach expiry or have expired in certain regions, the market for generic nintedanib esylate API has seen increased activity from Indian and Chinese manufacturers. These companies specialize in complex organic synthesis and possess the capacity to produce high-purity APIs at scale.

WHAT ARE THE KEY INTERMEDIATES AND CRITICAL RAW MATERIALS FOR NINTEDANIB ESYLATE SYNTHESIS?

The synthesis of nintedanib esylate involves several key chemical intermediates. The complexity of these molecules necessitates a robust supply chain for the precursor chemicals and reagents. The primary synthetic route typically begins with relatively common organic building blocks and progresses through several sophisticated coupling and functionalization steps.

Key Intermediates:

1. Indolinone Core Structure: This bicyclic heterocycle forms the central scaffold of nintedanib. Its synthesis often involves multiple steps, starting from simpler aniline derivatives and employing cyclization reactions.
2. Aniline Moiety: A substituted aniline derivative is crucial for forming one of the side chains. The specific substituents on this aniline dictate the regioselectivity and reactivity in subsequent steps.
3. Benzoic Acid Derivative: A substituted benzoic acid derivative is typically coupled to the indolinone core. The esterification or amidation of this component is a critical step.
4. Piperazine Ring: The piperazine moiety is attached to the benzoic acid portion. Its incorporation often requires specific coupling agents and reaction conditions to ensure efficient linkage.

Critical Raw Materials and Reagents:

The synthesis relies on a range of specific raw materials and reagents, many of which are fine chemicals produced by specialized chemical suppliers.

• Aniline Derivatives: Substituted anilines, such as 4-amino-N-methyl-2-phenylaniline or its precursors, are vital.
• Indole Derivatives: Precursors for the indolinone ring formation, often derived from isatin or related compounds.
• Halogenated Aromatic Compounds: Used in cross-coupling reactions to build the carbon skeleton.
• Coupling Reagents: Palladium catalysts (e.g., palladium acetate, Pd(PPh₃)₄), ligands (e.g., phosphine ligands), and bases (e.g., potassium carbonate, triethylamine) are essential for C-C and C-N bond formation.
• Acylating Agents: For forming ester or amide linkages.
• Solvents: High-purity solvents are critical for reaction efficiency and product purity. Common examples include dimethylformamide (DMF), tetrahydrofuran (THF), acetonitrile, and alcohols.
• Acids and Bases: For pH adjustment, catalysis, and salt formation (e.g., hydrochloric acid, sodium hydroxide, acetic acid).
• Chiral Resolving Agents: If enantiomeric purity is a concern at any intermediate stage, specific resolving agents may be required.
• Nintedanib Base: The free base form of nintedanib, which is then converted to the esylate salt.

The supply of these raw materials is global, with significant manufacturing bases in China, India, and Europe. Geopolitical stability, trade policies, and the environmental regulations affecting chemical production in these regions can impact the availability and cost of these critical components.

WHAT IS THE PATENT LANDSCAPE SURROUNDING NINTEDANIB ESYLATE?

The patent landscape for nintedanib esylate is primarily governed by patents held by Boehringer Ingelheim, the originator. These patents cover the compound itself, its synthesis, formulations, and specific medical uses. The expiry of these patents is a critical factor for the entry of generic manufacturers into the market.

Patent Type	Patent Number (Example)	Filing/Grant Date (Approx.)	Expiry Date (Approx. for Key Patents)	Coverage
Compound Patent	US 7,723,337 B2	2003 / 2010	2023 (US)	The nintedanib molecule itself.
Process Patent	EP 1 830 301 B1	2006 / 2012	Varies by region	Specific synthetic routes.
Formulation Patent	WO 2014/053295 A1	2013 / 2014	Varies by region	Pharmaceutical compositions, e.g., capsules.
Medical Use Patent	US 9,089,450 B2	2012 / 2015	2030 (US, with extensions)	Treatment of IPF, NSCLC.

Key Considerations:

• Compound Patent Expiry: The primary compound patent has expired or is nearing expiry in major markets like the United States and Europe. This has opened the door for generic nintedanib esylate API production.
• Evergreening Strategies: Originator companies often file secondary patents covering specific polymorphs, salts, formulations, or new medical uses. These "secondary patents" can extend market exclusivity beyond the expiry of the core compound patent. For nintedanib, patents related to specific salts (like the esylate), crystalline forms, or novel formulations can still be active.
• Process Patents: While the compound patent is key for market entry, specific patented manufacturing processes can still pose a barrier. Generic manufacturers must develop non-infringing synthetic routes.
• Exclusivity Periods: Regulatory exclusivity periods, such as New Chemical Entity (NCE) exclusivity in the US and data exclusivity in Europe, provide additional market protection for the originator, running concurrently with patent terms.
• Litigation: Patent litigation is common in the pharmaceutical industry. Generic manufacturers often challenge originator patents, leading to complex legal battles that can influence market entry timelines.

The global patent strategy employed by Boehringer Ingelheim has been comprehensive, aiming to protect its commercial interests for nintedanib esylate across its lifecycle. Companies seeking to enter the generic market must conduct thorough freedom-to-operate analyses.

WHAT ARE THE REGULATORY AND QUALITY CONSIDERATIONS FOR NINTEDANIB ESYLATE MANUFACTURING?

The manufacturing of nintedanib esylate, like all pharmaceutical products, is subject to stringent regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. Compliance with Good Manufacturing Practices (GMP) is non-negotiable.

Key Regulatory and Quality Aspects:

1. GMP Compliance: Manufacturers of both the API and the finished drug product must adhere to current GMP guidelines. This includes robust quality management systems, detailed batch records, validation of processes and analytical methods, and control of the manufacturing environment.
2. API Master File (APIMF) / Drug Master File (DMF): API manufacturers typically submit an APIMF (in Europe) or DMF (in the US) to regulatory agencies. This confidential document details the chemistry, manufacturing, and controls (CMC) of the API. Finished drug product manufacturers reference these filings in their marketing authorization applications.
3. Impurity Profiling: Identification, quantification, and control of process-related impurities, degradation products, and residual solvents are critical. Limits for impurities are set by regulatory guidelines (e.g., ICH Q3A, Q3C) and must be rigorously monitored. Nintedanib esylate's complex structure means a thorough understanding of potential process impurities is essential.
4. Polymorphism: Nintedanib esylate can exist in different crystalline forms (polymorphs). Regulatory agencies require manufacturers to control and characterize the specific polymorphic form used in the drug product, as different forms can affect solubility, bioavailability, and stability.
5. Stability Studies: Comprehensive stability testing under various conditions (temperature, humidity, light) is required to establish the shelf life and storage conditions for both the API and the finished drug product.
6. Supply Chain Security and Traceability: Ensuring the integrity and authenticity of raw materials and intermediates throughout the supply chain is paramount. Measures to prevent counterfeiting and diversion are also critical.
7. Environmental, Social, and Governance (ESG) Factors: Increasingly, regulatory bodies and investors are scrutinizing the environmental impact and social responsibility of pharmaceutical manufacturing, including chemical synthesis processes and waste management.

Failure to meet these regulatory and quality standards can result in warning letters, import alerts, product recalls, and significant reputational damage, ultimately impacting patient safety and commercial viability.

WHAT ARE THE POTENTIAL SUPPLY CHAIN RISKS FOR NINTEDANIB ESYLATE?

The global nature of pharmaceutical supply chains exposes nintedanib esylate manufacturing to a variety of risks that can disrupt production and availability.

Key Supply Chain Risks:

• Geopolitical Instability: Reliance on raw materials and intermediates from specific countries (e.g., China, India) makes the supply chain vulnerable to trade disputes, export/import restrictions, or regional conflicts. For instance, changes in China's environmental enforcement policies have previously led to temporary shutdowns of chemical plants.
• Raw Material Shortages and Price Volatility: The synthesis of nintedanib esylate utilizes specialty chemicals. Disruptions in the production of these precursor chemicals due to plant outages, natural disasters, or increased demand can lead to shortages and significant price increases.
• Logistics and Transportation Disruptions: Global shipping disruptions, port congestion, or increased freight costs can impact lead times and the timely delivery of raw materials and finished APIs.
• Regulatory Changes: Evolving regulations in different countries regarding chemical manufacturing, environmental standards, or import/export controls can necessitate costly process changes or create compliance hurdles.
• Quality Control Failures: A single quality lapse at an API or intermediate supplier can lead to batch rejection, regulatory actions against the finished product manufacturer, and potential drug shortages.
• Intellectual Property Disputes: Litigation related to process patents or challenging originator compound patents can create uncertainty and delay generic market entry, impacting investment and production planning.
• Dependence on a Limited Number of Suppliers: Over-reliance on a single or a small number of suppliers for critical intermediates or APIs creates a single point of failure.
• Natural Disasters and Pandemics: As demonstrated by recent global events, pandemics and natural disasters can severely disrupt manufacturing operations, labor availability, and global logistics.

Mitigating these risks requires a robust supply chain strategy that includes supplier diversification, rigorous due diligence, inventory management, and contingency planning.

STRATEGIC IMPLICATIONS FOR PHARMACEUTICAL COMPANIES

For pharmaceutical companies involved in the development, manufacturing, or commercialization of nintedanib esylate, understanding the supply chain dynamics is critical for strategic decision-making.

Strategic Considerations:

1. Vertical Integration vs. Outsourcing: Companies must evaluate the benefits and risks of in-house API manufacturing versus outsourcing to CMOs or specialized API producers. Originator companies may retain control over key early-stage intermediates to protect proprietary processes, while generic manufacturers often rely heavily on contract synthesis.
2. Supplier Qualification and Auditing: Implementing a stringent supplier qualification program, including regular audits of manufacturing sites and quality systems, is essential to ensure consistent API quality and regulatory compliance.
3. Geographic Diversification of Suppliers: Reducing reliance on a single country or region for critical raw materials and intermediates can mitigate geopolitical and logistical risks. Developing secondary suppliers is a key risk management strategy.
4. Contractual Agreements: Robust supply agreements with clear quality specifications, delivery schedules, and pricing clauses are necessary. Provisions for force majeure and supplier default should be included.
5. Intellectual Property Management: For originator companies, proactive patent portfolio management and defense are crucial. For generic companies, comprehensive freedom-to-operate analyses and development of non-infringing processes are paramount.
6. Investment in Supply Chain Resilience: Companies should consider investments in technology for supply chain visibility, risk assessment tools, and building buffer inventories for critical components where appropriate.
7. Long-Term Cost Optimization: While cost is a factor in sourcing, long-term strategic partnerships that ensure reliable supply and consistent quality often provide greater value than purely price-driven decisions.

The nintedanib esylate market, driven by both originator products and emerging generics, demands a sophisticated understanding of its complex manufacturing ecosystem. Strategic foresight in supply chain management will be a key differentiator.

KEY TAKEAWAYS

• Nintedanib esylate API manufacturing is primarily undertaken by originator Boehringer Ingelheim and a growing number of generic API producers in China and India.
• The synthesis involves complex organic chemistry, relying on specific substituted aniline and indolinone intermediates, alongside various coupling reagents and fine chemicals.
• The patent landscape, dominated by Boehringer Ingelheim's core compound and secondary patents, is gradually opening for generic competition as primary patents expire, though litigation remains a factor.
• Manufacturing is subject to rigorous GMP standards, requiring stringent impurity control, polymorph characterization, and stability testing by global regulatory authorities.
• Supply chain risks include geopolitical instability, raw material volatility, logistics disruptions, and quality failures, necessitating robust risk mitigation strategies.
• Strategic imperatives for companies include supplier diversification, rigorous qualification, IP management, and investment in supply chain resilience to ensure continuity and market access.

FREQUENTLY ASKED QUESTIONS

1. Which companies are considered the primary suppliers of nintedanib esylate API for the generic market? Primary suppliers for the generic market include Hangzhou Zhongxin Chem, Jiangsu Hansoh Pharmaceutical, Laurus Labs, and Neuland Laboratories.

2. What are the main geographical hubs for the production of critical raw materials and intermediates for nintedanib esylate? Key production hubs for critical raw materials and intermediates are located in China and India, with some specialized chemicals also sourced from Europe.

3. How does patent expiry impact the supply of nintedanib esylate? Patent expiry of the core nintedanib compound patent allows for the entry of generic API manufacturers, increasing supply options and potentially reducing API costs. However, secondary patents can influence the timeline and scope of generic market entry.

4. What are the primary quality control challenges in nintedanib esylate manufacturing? Key challenges include stringent control of process-related impurities, ensuring the correct crystalline polymorph is consistently produced, and maintaining stability of the API throughout its shelf life.

5. What is the role of contract manufacturing organizations (CMOs) in the nintedanib esylate supply chain? CMOs play a significant role in the formulation and packaging of the final drug product. Some CMOs may also be involved in specific synthesis steps or the production of intermediates for API manufacturers.

CITATIONS

[1] U.S. Food & Drug Administration. (n.d.). Patent Information. Retrieved from [FDA website for patent information] (Note: Specific patent numbers were used as examples, but direct links to constantly changing FDA patent databases are impractical for this format. Pharmaceutical patent databases such as Orange Book or commercial databases like Derwent or PatSnap are typical professional resources).

[2] European Medicines Agency. (n.d.). Human Medicines. Retrieved from [EMA website for medicine information] (Note: Similar to FDA, specific links to patent information are dynamic. Regulatory agency websites and commercial patent databases are primary sources).

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website for guidelines] (Note: Specific ICH guideline documents like Q3A, Q3C are foundational for impurity control).